Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Abaxis and LamdaGen Corporation Enter Into R&D Diagnostic Collaboration

Abstract:
Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point-of-care blood instrumentation and consumables to the medical, research and veterinary markets, and privately-held LamdaGen Corporation, an optical biosensor company, announced today an R&D agreement to integrate LamdaGen's high- sensitivity Plasmonic ELISA technology on the Abaxis Piccolo and VetScan rotors. System feasibility testing is currently underway.

Abaxis and LamdaGen Corporation Enter Into R&D Diagnostic Collaboration

Union City and Menlo Park, CA | Posted on October 26th, 2013

LamdaGen's patented biosensor platform is based upon LSPR (Localized Surface Plasmon Resonance) and provides rapid, quantitative diagnostic results with broad dynamic range and detection levels in the femtomolar range.

"We believe that LamdaGen's technology will provide a unique opportunity for Abaxis to integrate a high sensitivity immuno-based system onto our existing rotor-based platforms. This would allow us to provide both our existing clinical chemistry menu together with a wide range of high-sensitivity immunoassays, all within the scope of our present designs. If proven viable, both medical and veterinary customers will be able to simultaneously analyze for chemistry parameters as well as for infectious disease, hormones and a wide range of other markers on the same rotor," commented Clint Severson, Chief Executive Officer of Abaxis. "The ability to unify both diagnostic systems onto our existing rotor will greatly expand Abaxis' global diagnostic offerings."

"Abaxis is a leader in the POC industry, and we are very excited to collaborate with them in shaping the future of diagnostic testing," added Randy Storer, Chief Executive Officer of LamdaGen.

####

About LamdaGen Corporation
LamdaGen Corporation is a privately funded biosensor company that provides LSPR (Localized Surface Plasmon Resonance) diagnostic platforms and analytical products to the Life Science industry as well as functional nanomaterials to support various applications in plasmonics, cleantech and energy. Founded in 2005 and headquartered in Menlo Park, California, the company’s products are based upon its patented nano-structured surface technologies which produce highly robust sensors in the form of metallic thin films - and are the first commercially available LSPR-based products.

LamdaGen’s Plasmonic ELISA is fast, highly sensitive and ideally suited for In-Vitro and POC diagnostic systems, facilitating detection limits into the femtomolar range. The company licenses the platform to diagnostic companies for integration into their existing IVD devices or advanced systems under development.

About Abaxis

Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer. The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of- care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections, Parvovirus, Giardia and Lyme disease. Abaxis, through its AVRL division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide. For more information, visit www.abaxis.com.

For more information, please click here

Contacts:
Alice Huang


LamdaGen Corporation
Randy Storer
Chief Executive Officer
650-571-5816

Abaxis, Inc.
Clint Severson
Chief Executive Officer
510-675-6500

Lytham Partners, LLC
Joe Dorame
Robert Blum
Joe Diaz
602-889-9700

Copyright © LamdaGen Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells: NUS study shows that delivery of Epirubicin by nanodiamonds resulted in a normally lethal dosage of Epirubicin becoming a safe and effective dosage for treatment of liver cancer January 26th, 2015

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

Nanomedicine

Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells: NUS study shows that delivery of Epirubicin by nanodiamonds resulted in a normally lethal dosage of Epirubicin becoming a safe and effective dosage for treatment of liver cancer January 26th, 2015

Teijin to Participate in Nano Tech 2015 January 22nd, 2015

2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015

Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015

Announcements

Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells: NUS study shows that delivery of Epirubicin by nanodiamonds resulted in a normally lethal dosage of Epirubicin becoming a safe and effective dosage for treatment of liver cancer January 26th, 2015

GS7 Graphene Sensor maybe Solution in Fight Against Cancer January 25th, 2015

NANOPOSTER 2015 - 5th Virtual Nanotechnology Conference - call for abstracts January 24th, 2015

Nanosensor Used for Simultaneous Determination of Effective Tea Components January 24th, 2015

Alliances/Partnerships/Distributorships

Smart keyboard cleans and powers itself -- and can tell who you are January 21st, 2015

DNA 'glue' could someday be used to build tissues, organs January 14th, 2015

GLOBALFOUNDRIES and Linear Dimensions to Offer Joint Analog Solution For Fast-Growing Wearables and MEMs Sensors Markets January 9th, 2015

Nanowire clothing could keep people warm -- without heating everything else January 7th, 2015

Research partnerships

Promising use of nanodiamonds in delivering cancer drug to kill cancer stem cells: NUS study shows that delivery of Epirubicin by nanodiamonds resulted in a normally lethal dosage of Epirubicin becoming a safe and effective dosage for treatment of liver cancer January 26th, 2015

Wearable sensor clears path to long-term EKG, EMG monitoring January 20th, 2015

Graphene enables all-electrical control of energy flow from light emitters: First signatures of graphene plasmons at telecommunications wavelength revealed January 20th, 2015

Charge instability detected across all types of copper-based superconductors: Findings may help researchers synthesize materials that can superconduct at room temperature January 16th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE